The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates

Drug Updates

November 1, 2011 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

According to a meta-analysis published in JAMA, the anti–interleukin (IL)-12/23 agents ustekinumab and briakinumab and the anti–tumor necrosis-alpha (TNF-α) agents adalimumab, etanercept, and infliximab do not increase the rate of major adverse cardiovascular events (MACE).1 Randomized, placebo-controlled, double-blind, monotherapy studies in patients with chronic plaque psoriasis were evaluated. More than 10,000 patients met the inclusion criteria in 22 randomized controlled trials. The primary outcome was a major adverse cardiovascular event, a composite endpoint of myocardial infarction (MI), cerebrovascular accident, or cardiovascular death during the placebo-controlled phase of the study in patients that received at least one dose of placebo or the study drug. All studies had at least a 12-week placebo-controlled phase, except for the infliximab studies, which had a 10-week placebo-controlled phase. The event rates were as follows: five of the 1,471 patients that received ustekinumab and five of the 1,428 patients that received briakinumab had an MI or stroke or died of heart-related causes, compared with none of the 1,474 patients given placebo. The investigators noted that the difference did not reach statistical significance. One of the 1,032 adalimumab-treated patients had an event, which was concluded to be “no difference” compared with placebo-treated patients. No patients that received etanercept (n=1,679) or infliximab (n=1,147) had a MACE. The briakinumab event rate was further scrutinized by the investigators, and the investigational studies were discontinued to further evaluate the potential mechanisms related to the MACE rates in these patients. Additionally, the manufacturer amended the open-label continuation trials to withdraw any patients with two or more predefined cardiovascular risk factors who had not experienced failure of prior anti–TNF-α therapies. The authors note that until further data are available, clinicians should use extra vigilance of cardiovascular risk factors when beginning anti–IL-12/23 therapies in patients with psoriasis.

You Might Also Like
  • Drug Updates
  • Drug Updates: Apremilast, Belimumab, and More
  • Drug Updates
Explore This Issue
November 2011
Also By This Author
  • Etanercept Biosimilars Promising in Clinical Studies

Bisphosphonates (e.g., alendronate, etidronate, ibandronate, risedronate, risedronate delayed release, tiludronate), were evaluated on September 9, 2011 at a Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory meeting.2,3 Bisphosphonate studies have shown that these agents have proven beneficial within the first three years of treatment in preventing osteoporosis fractures. However, when treatment is continued beyond five years, there does not appear to be a use benefit compared with using “no drug.” Additionally, women who have stopped taking bisphosphonates after five years of treatment seem to have a similar risk of fracture reduction and amount of increased bone density compared with women who continue to receive bisphosphonates. In regard to side effects such as unusual femur breaks, osteonecrosis of the jaw, or esophageal cancer, there is no conclusive evidence that bisphosphonates cause these effects. However, these serious but rare effects are difficult to study and cannot be ruled out as being caused by bisphosphonates. The long-term safety of bisphosphonates is still unclear due to conflicting study results. (See the October 2011 issue of Drug Safety Quarterly, available at www.rheumatology.org in the “Publications” menu, for more information.)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Anti–IL-12/23 agents ustekinumab and briakinumab and the anti–TNF-a agents adalimumab, etanercept, and infliximab do not increase the rate of MACE.

As also noted in the October 2011 Drug Safety Quarterly, Citalopram has recently been identified as causing dose-dependent QT interval prolongation.4,5 Electrocardiogram changes can lead to the fatal arrhythmia called Torsade de Pointes. It is therefore recommended that this antidepressant no longer be prescribed at doses greater than 40 mg per day. Additionally, citalopram should not be used in patients with congenital long QT syndrome. Patients with congestive heart failure, bradyarrhythmias, or who are predisposed to hypokalemia or hypomagnesemia due to concomitant illness or drugs are at a higher risk of developing Torsade de Pointes. The citalopram drug label, including both brand and generic formulations, have been updated to include this warning. It is not clear whether these effects are seen with the S-enantiomer escitalopram.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: antiinflammatory, Approvals, Autoimmune, Drugs, FDA, Pipeline, Safety, tumor necrosis factorIssue: November 2011

You Might Also Like:
  • Drug Updates
  • Drug Updates: Apremilast, Belimumab, and More
  • Drug Updates
  • Drug Updates

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)